跳至主要内容
临床试验/2023-510312-40-00
2023-510312-40-00招募中4 期

Active vitamin D for secondary hyperparathyroidism after bariatric surgery: a multicenter randomized controlled trial (ActiVitD)

Academisch Ziekenhuis Leiden5 个研究点 分布在 1 个国家目标入组 130 人开始时间: 2024年11月4日最近更新:

试验速览

阶段
4 期
状态
招募中
入组人数
130
试验地点
5
主要终点
Normalization of PTH (and thus recovery of secondary hyperparathyroidism) at 2 years after diagnosis and start of treatment in one of the study groups. Secondary hyperparathyroidism will be defined as PTH at the upper limit or above the labs reference value combined with a normal or decreased serum calcium level (in patients with 25(OH)D >50 nmol/L

研究概览

简要总结

To investigate the effect of alfacalcidol on the treatment of secondary hyperparathyroidism in patients after RYGB

入排标准

年龄范围
18 years 至 65+ years(18-64 Years, 65+ Years)
接受健康志愿者

入选标准

  • Men and both pre- and postmenopausal women who have had Roux-en-Y-gastric bypass surgery, aged 18 years or above, and present with secondary hyperparathyroidism after surgery, with a vitamin D sufficient state (>50 nmol/l), and only on standard supplementation, are included
  • Provide informed consent prior to any specific study procedure

排除标准

  • Patients who are already on active treatment for osteoporosis before inclusion
  • Patients with chronic kidney disease defined as eGFR < 60 ml/min
  • Patients who had a bariatric intervention before and are re-operated
  • Patients that are on chronic steroid use, for example for inflammatory conditions
  • Patients that appear to have hypercalcemia on screening
  • Patients with known inflammatory conditions (i.e. rheumatoid arthritis)
  • Patients that have an active pregnancy wish

结局指标

主要结局

Normalization of PTH (and thus recovery of secondary hyperparathyroidism) at 2 years after diagnosis and start of treatment in one of the study groups. Secondary hyperparathyroidism will be defined as PTH at the upper limit or above the labs reference value combined with a normal or decreased serum calcium level (in patients with 25(OH)D >50 nmol/L

Normalization of PTH (and thus recovery of secondary hyperparathyroidism) at 2 years after diagnosis and start of treatment in one of the study groups. Secondary hyperparathyroidism will be defined as PTH at the upper limit or above the labs reference value combined with a normal or decreased serum calcium level (in patients with 25(OH)D >50 nmol/L

次要结局

  • Decrease in BMD (defined as 3% decrease in T-score at the lumbar spine and 5% decrease in T-score at the hip / forearm), measured at 1 and 2 years after inclusion
  • Quality of life is measured after inclusion and thereafter every 6 months with the OBESI-Q questionnaire

研究者

申办方类型
Hospital/Clinic/Other health care facility
责任方
Principal Investigator
主要研究者

N.M. Appelman-Dijkstra

Scientific

Academisch Ziekenhuis Leiden

研究点 (5)

Loading locations...

相似试验